StreetInsider.com News Articles

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Mon, 13 Jul 2026 07:30:00 -0400

H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)

Wed, 01 Jul 2026 07:05:11 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ: CGTX).

The analyst commented: "Cognition Therapeutics recently reported that it has received written feedback from the FDA following its recent meeting with agency reviewers. The FDA agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached alignment with the company on key aspects of a pivotal trial to support a New Drug Application (NDA). The registrational program is expected to begin in mid-2027. Cognition expects the Phase 3 study to enroll people with DLB who experience psychosis

Form 8-K COGNITION THERAPEUTICS For: Jun 24

Wed, 24 Jun 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260624/26682235.html

Form 8-K COGNITION THERAPEUTICS For: Jun 24

Wed, 24 Jun 2026 07:39:00 -0400

si-local-file:///var/storage/secattach/20260624/26682235.html

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it received written feedback from the U.S. Food and Drug Administration following a recent meeting, in which the agency agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached alignment on key aspects of a pivotal trial design to support a New Drug Application for zervimesine (CT1812).

The registrational program is expected to begin in mid-2027. The planned Phase 3 study will enroll patients with DLB who experience hallucinations and delusions, including those on stable background treatment with off-label antipsychotic medications. Participants will be randomized to receive either

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial

Wed, 24 Jun 2026 07:30:32 -0400

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Wed, 24 Jun 2026 07:30:00 -0400

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -
- Company Developing NPI as a Measure of DLB Psychosis -

PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) following its recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Wed, 24 Jun 2026 07:30:00 -0400

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -
- Company Developing NPI as a Measure of DLB Psychosis -